78.63% of #GinkgoBioworks ( $DNA) stock is owned by #Institutional #investors.
Here are some of the major institutional shareholders:
ARK Investment Management LLC owns a significant number of shares in Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). As of the most recent filings, they held 182,192,185 shares during the 3rd quarter of 2023.
Equitec Proprietary Markets LLC:
Holds 672,488 shares (0.5% of the portfolio).
Sumitomo Mitsui Trust Holdings Inc.:
Holds 55,865,048 shares (2.595% of the portfolio).
(Note: M. Potter who served as President, Chief Executive Officer, and Chair of the board of Sumitomo Pharma America, and as the Chief Executive Officer of Sumitovant Biopharma, the parent company of five biotechnology companies, was added to the board of Ginkgo BioWorks on April 29th)
Salem Investment Counselors Inc.:
Holds 4,758,585 shares (0.221% of the portfolio).
Vanguard Group Inc.:
Holds 132,780,095 shares (6.169% of the portfolio).
Lingotto Investment Management LLP:
Holds 8,511,301 shares (0.402% of the portfolio).
Additionally, during the previous two years, a total of 228 institutional investors and hedge funds held shares of Ginkgo Bioworks.
Some of the most heavily invested institutions include Baillie Gifford & Co., ARK Investment Management LLC, and Nikko Asset Management Americas Inc..
Institutional investors play a significant role in Ginkgo Bioworks’ ownership structure, with a mix of large investment firms and hedge funds holding substantial stakes in the company
Founded in 2008 by five #Scientists from #MIT, Ginkgo Bioworks is headquartered in #Boston.
Their mission is to use #Biology to grow better products across diverse markets.
They have developed a cell programming platform that enables the growth of biotechnology.
Ginkgo’s platform allows for programming cells and designing organisms that behave in pre-defined ways.
They work with various industries, from food to fragrance to pharmaceuticals.
- - - - - - -
#Ginkgo collaborates with various organizations and companies like:
Pfizer
Pfizer has entered into a multi-target RNA discovery collaboration with Ginkgo Bioworks, cell engineering.
Ginkgo also collaborates with these partners:
#Motif #FoodWorks:
Changing the future of #food.
#Bayer:
Designing #probiotics for plants.
#Allonnia:
Enabling bioremediation solutions.
#Aldevron:
Supporting the #Vaccine #SupplyChain.
#Cronos Group:
Unlocking potential in #Cannabinoids.
#Synlogic:
Engineering living #Medicines.
#Moderna:
Optimizing vaccine processes.
#IARPA:
Protecting valuable technology.
#Robertet:
Producing cultured ingredients.
And more